Skip to content

GLP-1 diet: what to eat, according to the labels and published guidance

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

A GLP-1 diet, going by the labels, is a reduced-calorie diet with increased physical activity. The Zepbound and Foundayo labels say to use the medicine that way. No GLP-1 label sets a meal plan. A 2025 joint advisory from four US nutrition and obesity societies cites protein targets of 1.2–1.6 g/kg/day, or 80–120 g/day, during active weight reduction on a GLP-1.

Source: FDA label (DailyMed)

Key takeaways

  • No GLP-1 label sets a meal plan. A registered dietitian can turn the label wording into an eating plan.
  • Injections aren't tied to meals. Semaglutide tablets are taken on an empty stomach, then you wait at least 30 minutes.
  • One 2025 advisory cites 1.2–1.6 g/kg/day or 80–120 g/day during active weight reduction. Your clinician sets your target.
  • Protein sources disagree on which body weight to use, so ask your clinician which one they want.
  • If you have kidney disease, your protein target is a decision for the clinician managing it.

Search for a “GLP-1 diet” and you’ll find hundreds of meal plans. None of them comes from an FDA label. This page sticks to what can be sourced: the diet wording on the labels, the food and drink rules that come with each form of medicine, the diets used in the trials the labels report, and the protein ranges published by professional groups. Every figure is quoted in the sources at the bottom of the page.

What do the labels say about diet?

The label instruction is short. The Zepbound prescribing information says to administer Zepbound “in combination with a reduced-calorie diet and increased physical activity.” The Foundayo Medication Guide tells patients to use Foundayo “with a reduced-calorie diet and increased physical activity.” When FDA approved Foundayo on April 1, 2026, the agency described the approval the same way: for use in combination with a reduced-calorie diet and increased physical activity.

For the type 2 diabetes medicines, the wording sits in the indication (the approved use) itself. Our drug records for Mounjaro, Ozempic, Rybelsus and Trulicity each give the first approved use as an adjunct (an add-on) to diet and exercise to improve glycemic control, which means blood sugar control.

That’s all the labels say. “Reduced-calorie” is left for you and your prescriber to define. If you want that turned into an eating plan, a registered dietitian is the professional who does it.

What diets were used in the label trials?

The labels describe what trial participants did alongside the medicine. These are descriptions of how the studies were set up, and they differ from trial to trial.

  • Wegovy Study 4. Patients received an initial 8-week low-calorie diet with a total energy intake of 1,000 to 1,200 kcal/day. That was followed by 60 weeks of a reduced-calorie diet (1200 to 1800 kcal/day) and increased physical activity (100 minutes a week, rising gradually to 200). At 68 weeks, average body-weight change was -16% with Wegovy 2.4 mg injection versus -5.7% with placebo (an inactive treatment).
  • Zepbound Study 3. Everyone completed a 12-week intensive lifestyle intervention first. Over the following 72 weeks, on a standard lifestyle intervention, body weight changed by -18.4% with Zepbound versus +2.5% with placebo.
  • Saxenda Study 3. Adults who had first lost at least 5% of body weight with a low-calorie diet changed by a further -4.9% on Saxenda versus +0.3% on placebo over 56 weeks. The label cautions that because the diet run-in (the diet before the trial) was a condition of taking part, the results may not reflect those expected in the general population.

Two cautions. These are separate trials of different medicines in different populations, so you can’t compare the results with each other. And the calorie ranges in Wegovy Study 4 were set and supervised by the study. They aren’t a target for you to adopt on your own.

Do I take my GLP-1 with food or on an empty stomach?

It depends on the form you take, and this is where the labels are most specific.

Weekly and daily injections

Injections aren’t tied to meals. The labels say Zepbound, Mounjaro, Wegovy injection and Ozempic injection are given once weekly at any time of day, with or without meals. Trulicity is once weekly, any time of day, with or without food. Saxenda is injected once daily at any time of day, without regard to the timing of meals.

Semaglutide tablets

Wegovy tablets, Rybelsus and Ozempic tablets have the strictest rule. Each label says to take one tablet once daily on an empty stomach in the morning with water, up to 4 ounces, and with no other liquid. After the tablet, the labels say to wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.

Foundayo

Foundayo is also a daily tablet, but its label says it’s taken with or without food.

If your morning routine makes the semaglutide tablet rule hard to follow, tell your prescriber or pharmacist. The pen, vial or pill comparison tool shows the forms side by side.

How much protein should I eat on a GLP-1?

No GLP-1 label in our records sets a protein target. The numbers people quote come from professional guidance, and the two documents written specifically for people on GLP-1 medicines are both from 2025. Many ranges use g/kg/day, which means grams of protein for each kilogram of body weight, each day.

The joint advisory. The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society published a joint advisory on nutritional priorities to support GLP-1 therapy for obesity. It says higher targets, such as 1.2–1.6 g/kg/day, “have also been proposed” during active weight reduction. As an alternative, it says an absolute protein target of 80–120 g/day, or 16%–24% of energy on a 2000 kcal/d diet, may enhance adherence (help people stick with it) while ensuring adequate intake.

The Delphi consensus. An international expert consensus on GLP-1-based therapies recommends 1.2–1.5 g/kg of actual body weight per day during the rapid weight loss phase. It pairs that with maintaining physical activity to preserve muscle mass, particularly in older adults or those at risk of sarcopenia (muscle loss). For the weight-maintenance phase it recommends protein of at least 0.8 g/kg/day, possibly more for older adults. The expert panel’s meetings and medical writing were funded by Nestlé Health Science, which is worth knowing when you read it.

For comparison, the US and Canadian Recommended Dietary Allowance for healthy adults is 0.80 g/kg/day. That’s a general-population reference value, not a weight-loss target.

The protein guidance page goes through all eight published ranges we track, including the ones written for older adults and for people after bariatric surgery. The protein calculator shows what each range works out to at your weight, side by side. It makes no individual recommendation, and neither do we.

Which body weight do the protein ranges use?

This matters more than it looks, and the sources are open about not agreeing. The joint advisory says that for individuals with obesity “it is unclear whether these goals should be based on actual body weight, corrected (adjusted or ideal) body weight, or fat-free mass, as the use of actual weight can significantly overestimate protein requirements.” The Delphi consensus uses actual body weight, and its authors note that this may overestimate needs in people with higher fat mass.

In practice, a per-kilogram range applied to your current weight gives a larger number than the same range applied to an ideal or adjusted weight. The absolute target in the joint advisory (80–120 g/day) avoids the question, which is one reason the advisory offers it. Ask your clinician which basis they want you to use before you settle on a figure.

Is there an upper limit?

The joint advisory says prolonged intake at or above 2 g/kg/day should be avoided. The PROT-AGE position paper for older adults notes that people with severe kidney disease who are not on dialysis may need to limit protein. If you have kidney disease, a protein target is a decision for the clinician managing it, not something to take from a general range.

Does a GLP-1 change how I take other pills with meals?

The labels flag one food-related issue. GLP-1 medicines slow stomach emptying. The Zepbound label says it “delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications,” and the Wegovy label says to monitor the effects of oral medications taken alongside it. If you take other tablets, especially ones with timing rules of their own, ask your pharmacist whether anything about your schedule should change.

Do Medicare and Medicaid programs include nutrition support?

Two federal programs tie GLP-1 coverage for weight management to lifestyle support.

Under the BALANCE Model in Medicaid, CMS says all beneficiaries receiving GLP-1s for weight management will be provided with access to a lifestyle support program, provided by the manufacturer at no cost. The Medicaid coverage page covers whether your state takes part.

The Medicare GLP-1 Bridge requires the prescriber to attest (formally state) that the drug is used in combination with lifestyle modification that includes structured nutrition and physical activity. The Bridge explainer has the exact criteria.

A registered dietitian can address meal plans, calorie targets, fiber, fluid and micronutrient targets, supplements and foods that ease or worsen side effects for your situation. Your prescriber can refer you to one.

Further down this page you may see a short list of meal-delivery and testing services. They’re commercial services, not medical recommendations, and none is needed to take a GLP-1 medicine. Our affiliate disclosure explains how those listings work.

Questions to take to your prescriber or dietitian

  1. What does “reduced-calorie” mean for me, in numbers?
  2. Which protein range do you want me to follow, and based on which body weight?
  3. Does my kidney function, age or activity level change that target?
  4. If I take a semaglutide tablet, how should I arrange breakfast and my other morning medicines around the 30-minute wait?
  5. Is a referral to a registered dietitian covered by my plan?

Services some people use alongside treatment

Some links on this page are affiliate links: if you sign up through them we may earn a commission at no extra cost to you. The cheapest legitimate option is always listed first, and payouts never affect rankings. How we make money.

  • CookUnity

    Chef-prepared meal delivery. Not a medical service.

    Visit CookUnity
  • Everlywell

    At-home lab test kits. Results are not a diagnosis; discuss them with your clinician.

    Visit Everlywell
  • Factor

    Prepared meal delivery. Not a medical service.

    Visit Factor
  • LetsGetChecked

    At-home lab test kits. Results are not a diagnosis; discuss them with your clinician.

    Visit LetsGetChecked
  • Withings

    Smart scales and health devices. Not required for treatment.

    Visit Withings

These are not medical recommendations and none is needed to take a GLP-1 medicine.

Frequently asked questions

Is there an official GLP-1 diet?

No. The Zepbound label says to use it in combination with a reduced-calorie diet and increased physical activity, and the Foundayo Medication Guide says the same. What a reduced-calorie diet looks like for you is a decision for your prescriber or a registered dietitian.

How much protein should I eat on a GLP-1?

Published guidance gives ranges, not one number. A 2025 joint advisory for adults taking GLP-1 medicines for obesity cites 1.2–1.6 g/kg/day during active weight reduction, or an absolute target of 80–120 g/day. A 2025 Delphi expert consensus recommends 1.2–1.5 g/kg of actual body weight per day during rapid weight loss. Your own target is for your clinician to set.

Do I have to take my GLP-1 with food?

It depends on the form. Weekly injections (Zepbound, Mounjaro, Wegovy, Ozempic, Trulicity) are given with or without meals, and Saxenda is injected without regard to meal timing. Foundayo is taken with or without food. Wegovy tablets, Rybelsus and Ozempic tablets are taken in the morning on an empty stomach with up to 4 ounces of water.

How long after a semaglutide tablet can I eat?

The labels for Wegovy tablets, Rybelsus and Ozempic tablets say to wait at least 30 minutes after taking the tablet before eating food, drinking beverages or taking other oral medications. You take the tablet itself with water only, up to 4 ounces, and no other liquid.

What diet was used in the Wegovy and Zepbound trials?

Trial diets varied. In Wegovy Study 4, patients had an initial 8-week low-calorie diet of 1,000 to 1,200 kcal/day, then 60 weeks of a reduced-calorie diet of 1200 to 1800 kcal/day with increased physical activity. Zepbound Study 3 began with a 12-week intensive lifestyle lead-in. These describe how the trials were designed. They aren't instructions for you.

Should I calculate protein from my actual weight or my ideal weight?

The sources disagree, and they say so. The joint advisory states it's unclear whether goals should be based on actual body weight, adjusted or ideal body weight, or fat-free mass, and that actual weight can significantly overestimate protein requirements in people with obesity. The Delphi consensus uses actual body weight. Ask your clinician which basis they want you to use.

Do I need protein shakes or supplements on a GLP-1?

The published ranges on this page are about total daily protein from all sources. Whether a supplement makes sense for you is a question for your prescriber, pharmacist or registered dietitian.

Do older adults need more protein on a GLP-1?

The sources point that way. The Delphi consensus says protein of at least 0.8 g/kg/day is recommended in weight maintenance, possibly more for older adults, citing ESPEN-endorsed recommendations of at least 1.0–1.2 g/kg/day for healthy older people. The PROT-AGE group recommends at least 1.0 to 1.2 g/kg/day for people over 65. Neither was a GLP-1 trial.

Sources (21)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
  2. 2.
    FDA label (DailyMed): Foundayo Medication Guide (in the prescribing information)
    “Use FOUNDAYO with a reduced-calorie diet and increased physical activity.”
  3. 3.
    FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 8
    “In Study 4, patients received an initial 8-week low-calorie diet (total energy intake 1,000 to 1,200 kcal/day) followed by 60 weeks of a reduced-calorie diet (1200 to 1800 kcal/day) and increased physical activity (100 mins/week with gradual increase to 200 mins/week).”
  4. 4.
    FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 4
    “Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight. % Change from randomization at Week 72: Placebo N = 292: 2.5; ZEPBOUND MTD (10 mg or 15 mg) N = 287: -18.4”
  5. 5.
    FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 4
    “In Study 3, statistically significantly more patients randomized to SAXENDA than placebo had not gained more than 0.5% of body weight from randomization to Week 56.”
  6. 6.
    FDA label (DailyMed): Saxenda prescribing information, section 14.1
    “Because losing at least 5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population.”
  7. 7.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
  8. 8.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
  9. 9.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water”
  10. 10.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
  11. 11.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Take FOUNDAYO orally once daily, with or without food.”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND once weekly at any time of day, with or without meals.”
  13. 13.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Administer MOUNJARO once weekly, any time of day, with or without meals.”
  14. 14.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
  15. 15.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.”
  16. 16.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Administer TRULICITY once weekly, any time of day, with or without food.”
  17. 17.
    FDA label (DailyMed): Saxenda prescribing information, section 2.1
    “Inject SAXENDA subcutaneously once daily at any time of day, without regard to the timing of meals.”
  18. 18.
    FDA label (DailyMed): Zepbound prescribing information, section 7.2
    “ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.”
  19. 19.
    FDA label (DailyMed): Wegovy prescribing information, section 7.2
    “In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY.”
  20. 20.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “All beneficiaries receiving GLP-1s for weight management under the BALANCE model in Medicaid will be provided with access to a lifestyle support program, provided by the manufacturer at no cost.”
  21. 21.
    FDA: FDA Approves First New Molecular Entity Under National Priority Voucher Program
    “The U.S. Food and Drug Administration today approved Foundayo (orforglipron), marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program. [...] Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”